Page last updated: 2024-10-28

phenelzine and Obesity

phenelzine has been researched along with Obesity in 3 studies

Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Phenelzine has no interest to be combined with low doses of resveratrol for treating/preventing obesity, when considering the VHFD mouse model."7.80Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. ( Bertrand, C; Cadoudal, T; Carpéné, C; Gomez, A; Gomez-Zorita, S; Grès, S; Gupta, R; Iffiu-Soltész, Z; Mercader, J; Rancoule, C, 2014)
"Phenelzine has been suggested to have an antiobesity effect by inhibiting de novo lipogenesis, which led us to investigate the metabolic effects of oral chronic phenelzine treatment in high-sucrose-drinking mice."3.88Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice. ( Carpéné, C; Chaplin, A; Gómez-Zorita, S; Mercader, J, 2018)
"Phenelzine has no interest to be combined with low doses of resveratrol for treating/preventing obesity, when considering the VHFD mouse model."3.80Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. ( Bertrand, C; Cadoudal, T; Carpéné, C; Gomez, A; Gomez-Zorita, S; Grès, S; Gupta, R; Iffiu-Soltész, Z; Mercader, J; Rancoule, C, 2014)
"Inhibition of semicarbazide-sensitive amine oxidases (SSAO) and monoamine oxidases (MAO) reduces fat deposition in obese rodents: chronic administration of the SSAO-inhibitor semicarbazide (S) in combination with pargyline (MAO-inhibitor) has been shown to reduce body weight gain in obese Zucker rats, while (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, an SSAO- and MAO-B inhibitor, has been reported to limit weight gain in obese and diabetic mice."1.35Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. ( Abello, V; Carpéné, C; Fève, B; Iffiú-Soltész, Z; Mercier, N; Valet, P, 2008)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carpéné, C3
Gómez-Zorita, S2
Chaplin, A1
Mercader, J2
Gupta, R1
Grès, S1
Rancoule, C1
Cadoudal, T1
Gomez, A1
Bertrand, C1
Iffiu-Soltész, Z2
Abello, V1
Mercier, N1
Fève, B1
Valet, P1

Other Studies

3 other studies available for phenelzine and Obesity

ArticleYear
Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice.
    International journal of molecular sciences, 2018, Sep-25, Volume: 19, Issue:10

    Topics: Adipose Tissue, White; Adiposity; Administration, Oral; Animals; Fatty Acids, Nonesterified; Lipogen

2018
Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice.
    European journal of nutrition, 2014, Volume: 53, Issue:8

    Topics: Adipocytes; Adipogenesis; Animals; Blood Glucose; Body Composition; Diet, High-Fat; Dose-Response Re

2014
Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors.
    Pharmacological research, 2008, Volume: 57, Issue:6

    Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Adiposity; Amine Oxidase (Copper-Containing); Ani

2008